The reduction of Cu(NO3)2 by HStBu in CH3CN under Ar atmosphere produces a light-yellow solution containing numerous {Cux(StBu)y} species. The addition of different pyridines (py-R) into this solution results in the formation of {Cu6(StBu)4} hexanuclear complexes. The slow Et2O diffusion leads to crystals of [Cu6(StBu)4(2-Me-py)5(CH3CN)(NO3)](NO3) (1), [Cu6(StBu)4(Me3py)4(NO3)2]·3.5CH3CN (2a), [Cu6(StBu)4(Me3py)5(NO3)](NO3)·5CH3CN (2b), (NHEt3)[Cu6(StBu)4(CH3CN)3(NO3)3]·H2O (3), [Cu6(StBu)4(2-Br-py)4(NO3)2]·2-Br-Py (4), [Cu6(StBu)4(3-Br-py)6][Cu6(StBu)4(CH3CN)6](NO3)4·9CH3CN (5), and [Cu6(StBu)4(3-Cl-py)6][Cu6(StBu)4(CH3CN)6](NO3)4·5CH3CN (6). The titled compounds were characterized by single crystal X-ray diffraction (SCXRD). The Cu···Cu contacts were analyzed with quantum chemical methods.
No takes yet. Share an insight, caveat, or question.
Sukhikh et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: